NewsBenzingaSignalé dimanche, Viking Therapeutics rapporte que 74 % des participants sous VK2735 en sous-cutané ont amélioré leur catégorie d’IMC contre 15 % sous placebo après 13 semaines, avec une amélioration des marqueurs cardiométaboliques Signalé dimanche, Viking Therapeutics rapporte que 74 % des participants sous VK2735 en sous-cutané ont amélioré leur catégorie d’IMC contre 15 % sous placebo après 13 semaines, avec une amélioration des marqueurs cardiométaboliques Benzinga 2026.11.16 05:21 (GMT+0) Open on Benzinga Other news South Korean Lawmaker Proposes Virtual Asset AML Bill, Exchanges Face Fines of Up to 100 Million Won Mark Carney Warns Canada Could Turn to China for Autos if Trade Talks With Trump Administration Fail: ‘Not Leverage. But Action, Reaction’ Italian Robotics Startup Mosaico Raises €7.5 Million Seed Round Ryan Cohen Wants Someone Who Can ‘Move Fast’ and ‘Own Results’ at GameStop as CEO Looks to Build His Next Big Move: Here’s How You Can Apply Are Wall Street Analysts Bullish on Eversource Energy Stock? Reported Saturday, Avexitide Meets Phase 3 LUCIDITY Primary Endpoint In Post-Bariatric Hypoglycemia, Cutting Level 2/3 Events 0.55 Per Week Versus 1.24 For Placebo, With No Treatment-Related Serious Adverse Events
Mark Carney Warns Canada Could Turn to China for Autos if Trade Talks With Trump Administration Fail: ‘Not Leverage. But Action, Reaction’
Ryan Cohen Wants Someone Who Can ‘Move Fast’ and ‘Own Results’ at GameStop as CEO Looks to Build His Next Big Move: Here’s How You Can Apply
Reported Saturday, Avexitide Meets Phase 3 LUCIDITY Primary Endpoint In Post-Bariatric Hypoglycemia, Cutting Level 2/3 Events 0.55 Per Week Versus 1.24 For Placebo, With No Treatment-Related Serious Adverse Events